“Gold rush towards oncology” has major implications for pharma patent deal-making
A leading pharmaceuticals intelligence firm is predicting a sharp rise in the value of cancer therapy sales, and its chief forecaster recently told IAM of an ongoing “gold rush towards oncology” among life sciences companies. A key strategic focus…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.